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Long-term Effects of West Nile Virus in Virginia 
Diana Ocampo 
 
ABSTRACT 
 
Objective: The purpose of this investigation was to describe the long-term effects and functional 
outcomes of patients in Virginia who were reported to the Virginia Department of Health with 
West Nile virus (WNV) non-neuroinvasive and neuroinvasive disease.  The study identified the 
duration of symptoms after initial illness, the number of persons who fully recovered versus the 
number who continue to be symptomatic and how patients’ quality of life differed after illness. 
 
Methods:  The study population was drawn from 60 human cases that met the surveillance case 
definition for non-neuroinvasive and neuroinvasive WNV illness in Virginia between 2002-
2004. Information was collected during personal interviews using a standard questionnaire.  The 
questionnaire included questions on demographics, clinical signs and symptoms, existing 
medical conditions and the respondents’ personal assessment of health.  Statistical analysis were 
used to compare pre and post illness symptoms, respondents vs. non-respondents, and non-
neuroinvasive respondents vs. neuroinvasive respondents.   
 
Results: 
Thirty-four patients were enrolled in the study. Five (14.7%) respondents had non-neuroinvasive 
disease and 29 (85.2%) had neuroinvasive disease. Thirty respondents (88.2%) reported being 
hospitalized.  Respondents with non-neuroinvasive disease spent a median of 3.5 (range, 0-7) 
days in the hospital and were unable to resume normal activities for a median of 17 (range, 7-
365) days.  Respondents with neuroinvasive disease spent a median of 7.5 (range, 0-82) days in 
the hospital and were unable to resume normal activities for a median of 127.50 days (range, 0-
1023). Two (40%) of the respondents that suffer from non-neuroinvasive illness were unable to 
resume normal activities for at least 90 days. Fifteen (51.7%) respondents with neuroinvasive 
disease were unable to resume normal activities for at least 90 days.  At the time of the interview, 
20% of respondents with non-neuroinvasive disease reported fatigue, tremors, arthralgia, 
paralysis and memory problems. Respondents with neuroinvasive disease reported fatigue 
(58.5%), weakness (51.7%), myalgias (37.9%), confusion (41.4%), and memory loss (55.2%).   
 
Conclusion: WNV illness, including non-neuroinvasive illness, may be more serious and 
prolonged than generally thought.  Neuroinvasive disease resulted in long-term morbidity and 
non-neuroinvasive disease resulted in work absenteeism and extended recovery periods.  The 
mortality rates and potential long-term effects associated with non-neuroinvasive and 
neuroinvasive illness emphasizes the importance of continuing to develop effective methods of 
targeting preventive education to high-risk populations while continuing to pursue longer-term 
solutions such as vaccines to prevent emerging infection. Further research is needed to document 
the long-term effects of WNV, especially in areas with a high number of WNV human cases 
with more non-neuroinvasive patients. WNV is an emerging infectious disease with a wide 
clinical spectrum and variable long-term effects; thus a public health concern.  
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 Introduction 
  West Nile virus (WNV) is a mosquito-borne pathogen that is indigenous to Africa, Asia, 
Europe, and Australia 1,2,21.  WNV belongs to the family Flaviviridae which also includes Saint 
Louis encephalitis (SLE) and Japanese encephalitis viruses.  Although outbreaks have occurred 
from these viruses in the past, WNV was unique because it caused a national epidemic, unlike 
the other arboviruses 27,22.   
  WNV was first discovered in the blood of a febrile woman from the West Nile province 
of Uganda in 1937 4, 20.  Human outbreaks occurred in Israel and Africa in the early 1950’s, and 
humans with neuroinvasive disease were reported in Romania, Russia, and Israel in the late 
1990’s5,6, 25 . 
The first North American human case of WNV infection identified in the United States 
was in Queens, New York, in the summer of 1999.  The outbreak resulted in 62 clinical cases, 
including seven deaths2,7.  Since that outbreak, WNV has spread rapidly south and west and in 
2002 reached the Pacific Coast.  WNV reached the West coast on September 2002 with one 
human case from Los Angeles County, in Southern California 28. 
Many states, including Virginia, detected human WNV infection for the first time in 
200228 .  For the years 1999 through 2001, the total number of US human WNV infection cases 
reported from the Centers for Disease and Control and Prevention (CDC) was 149, including 18 
deaths, from 27 states and the District of Columbia 28,8 (Table 1).  The number of human WNV 
cases in the U.S. increased dramatically to a peak of 9,862 in 2003 and decreased to 2,539 in 
2004 (Table 1) with 46 and 50 states reporting respectively in those years 33.    
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 Shortly after WNV was first detected in the U.S., the Virginia Department of Health 
established the Interagency Arbovirus Surveillance and Response Task Force, which developed a 
plan for detecting and responding to WNV and other arboviruses 32.  Surveillance activities 
aimed at detecting WNV infection in wild birds, mosquitoes, horses and humans began in 2000, 
which was the year WNV was first detected in Virginia in seven crows.  The first WNV positive 
mosquito pool in Virginia was detected in 2001, the first horse in 2001, and the first human in 
2002.  Although all arbovirus infections are on the reportable disease list, many cases may have 
been undetected because of a low index of suspicion.  With the advent of WNV, testing for all 
arboviruses increased.  Because the state Division of Consolidated Laboratory Service (DCLS) 
utilizes an arboviral panel that includes eastern equine encephalitis, St. Louis encephalitis, WNV 
and the California group of arboviruses, specimens submitted for testing for any of those 
infections are tested for all.  Although mild WNV disease is far more common than the severe 
diseases, mild cases are underrepresented in case counts because those persons are less likely to 
seek medical care, and testing of persons with mild WNV has traditionally been discouraged. 
 Birds are considered reservoirs of WNV and mosquitoes are vectors. Mosquitoes become 
infected after taking blood meals from birds that are infected with WNV and then passing the 
virus to other birds that they feed on.  WNV is amplified in at least 100 different bird species and 
several mosquito species during the bird-mosquito-bird cycle which occurs in warm months.  
This results in an increased likelihood of infection late in the season when a maximum number of 
birds and mosquitoes are infected with high levels of the virus. WNV is transmitted to humans 
most commonly through infected Culex mosquitoes 22.  However, a variety of mosquito species 
have been implicated in transmitting the virus depending on the geographic area and the species’ 
ability to transmit 34.  Humans and domestic animals are considered dead-end-hosts to the virus 
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and therefore WNV is not transmitted from person to person by mosquitoes; there is not enough 
viremia for a long enough time to continue the cycle 37.  Although human-to-human WNV 
infection is rare, it has occurred through blood transfusions, transplancental transfer, organ 
transplantation, and breast feeding 33.   
 WNV infection usually results in no symptoms (80%), mild symptoms (20%), or in a 
minority of infections serious neurologic disease 38.  WNV surveillance conducted on humans in 
Connecticut and New York, during October-November in 2000, reported 1 in 5 infected persons 
had a febrile illness, and approximately 1 in 150 infected persons had severe illness7, 30, 31.  In 
most literature, common symptoms reported are fever, headache, malaise, fatigue, muscle aches 
and joint pains26. WNV disease is classified as either neuroinvasive or non-neuroinvasive.  Non-
neuroinvasive infections are considered milder and lack neurologic manifestations. 
Neuroinvasive disease results from the virus traveling via the blood to the brain and infecting the 
central and peripheral nervous systems.  Symptoms used to define WNV neuroinvasive disease 
include fever and at least one of the following: acutely altered mental status such as 
disorientation or coma, acute signs of central or peripheral neurologic dysfunction, or pleocytosis 
33. Neuroinvasive diseases can manifest as encephalitis, meningitis, or acute flaccid paralysis 5, 7, 
17.The risk of developing neuroinvasive disease increases in patients over 50 years of age, while 
younger patients are more likely to develop non-neuroinvasive disease 31.  
Although numerous papers have described the clinical characteristics of hospitalized patients, the 
duration of symptoms has not been specifically addressed. The long-term consequences of WNV 
disease, both non-neuroinvasive and neuroinvasive, have not been well described for patients. 
An article by Sejvar et al. reports that persistent fatigue, headache, and myalgia are common 
long-term effects of neuroinvasive WNV disease. A recent article on neuroinvasive disease 
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reported that one third of cases were hospitalized and 60% were unable to return to pre-illness 
activity levels for a median of 150 days (range 90-180) 35.  Clinical characteristics of hospitalized 
human cases have been described, but the duration of various signs and symptoms associated 
with initial signs and symptoms have not been specifically addressed26,33.  Further research is 
needed to document the long-term effects of both neuroinvasive and non-neuroinvasive illnesses 
to determine the individual and medical burdens that WNV infection represent. 
OBJECTIVES 
 The purpose of this investigation is to describe the long-term effects and functional 
outcomes of patients in Virginia who were reported to the Virginia Department of Health with 
both types of WNV illness.  The study identified the duration of symptoms after initial illness, 
the number of persons who fully recovered versus the number who continue to be symptomatic,  
and how patients’ quality of life differed after illness.  
METHODS 
Data Collection 
  Although many suspected WNV cases were reported to VDH, cases were only counted if 
they met the surveillance case definition for probable or confirmed WNV illness. This included 
the clinical criteria in Figure 1 and positive laboratory test results from the Division of 
Consolidated Lab Services (DCLS) or another government public health laboratory.  Specific 
laboratory tests were required to differentiate WNV infections from other flaviviruses and move 
cases from the probable to confirmed category.  
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Figure 1. Clinical Criteria 
 
Neuroinvasive Disease: Requires the presence of fever and at least one of the following, as 
documented by a physician and in the absence of a more likely clinical explanation: 
• Acutely altered mental status (e.g., disorientation, obtundation, stupor, or coma), or 
• Other acute signs of central or peripheral neurologic dysfunction (e.g. paresis or  
      paralysis, nerve palsies, sensory deficits, abnormal reflexes, generalized convulsions, 
      or abnormal movements), or 
• Pleocytosis (increased white blood cell concentration in cerebrospinal fluid [CSF]) 
      associated with illness clinically compatible with meningitis (e.g., headaches or stiff  
      neck). 
Non-neuroinvasive Disease at minimum, the presence of documented fever, measured by the 
patient or clinician, the absence of neuroinvasive disease (above), and the absence of a more 
likely clinical explanation for the illness.  Involvement of non-neuroinvasive organs (e.g., heart, 
pancreas, liver) should be documented using standard clinical-laboratory criteria. 
 
After obtaining approval from Virginia Commonwealth University and the VDH’s 
Institutional Review Board, persons who met the case definition of WNV infection were 
identified and existing records were retrieved.  The state death registry was examined to 
determine whether any WNV patients were deceased.  All cases under the age of 18 and 
pregnant women were excluded to expedite IRB approval.  Demographic data, clinical data, 
information on initial diagnoses, and past health history that had been abstracted from medical 
records by VDH using a standard form were utilized by the investigator.  Verbal consent was 
obtained from respondents during telephone interviews and all available respondents were 
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interviewed using a standard questionnaire.  The questionnaire included questions on 
demographics, clinical signs and symptoms, existing medical conditions, health care and the 
respondents’ own assessment of general health before and after the illness (Table 2). 
Respondents were asked if they were acutely ill with any of 15 specific symptoms, how often 
they experienced the symptom before and after they became ill with WNV, and if they currently 
experience it (Table 3). Duration of symptoms was determined using self-reported illness 
information at the time of the interview and medical records.  The Instrumental Activities of 
Daily Living Scale (IADLS) was used to evaluate patients’ functional ability.   
 
Statistical Analysis 
Microsoft Office Excel 2003 and SPSS System for Windows, version 13.0 were used to analyze 
the collected data.  Frequencies and percentages of demographics, underlying illnesses, clinical 
syndrome and discharge status were used to compare respondents and non-respondents.  P-
values were calculated using chi-square for correlated proportions between symptoms before and 
after the WNF infection.  To calculate the p-values for the “before” and “after” symptoms, 
outcomes were split into dichotomous variables; never and sometimes were coded as one, and 
often and always were coded as two.  Frequencies, medians and ranges were calculated for the 
duration of the symptoms.   
RESULTS 
  In Virginia, for the years 2002 through 2004, 60 humans with WNV infection met the 
case definition as probable or confirmed cases. Of these, six were deceased, two were under the 
age of 18, and no contact information was available for seven.  Of the 45 eligible for inclusion, 
11 were lost to follow-up because one refused to participate, four could not be reached in at least 
four attempts, and six were not interviewed because current contact information was not 
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available.  The remaining 34 patients were enrolled in the study.  Medical information was 
available for all 60 cases.   
Interviews were conducted from June 6 to June 29, 2005. Respondents with missing 
responses or responses of “do not remember” were not included in the calculations for that 
particular variable.  Eleven of the 34 respondents had continuing symptoms they associated with 
their initial WNV illness. Table 4 shows the demographic and basic clinical information for the 
respondents and non-respondents.  The two groups were similar in age.  The median age of the 
respondents was 56.5 years (range 36-89).  Over half of the respondents were men (64.7%) 
(Table 4) and only 8.8% of the respondents were black.  There were over four times as many 
respondents with neuroinvasive disease (82.3%) than non-neuroinvasive disease, but only half of 
non-respondents had neuroinvasive diseases. Thirty respondents (88.2%) reported being 
hospitalized (median length of stay, 7 days [range, 0-82]) (Tables 5 & 11).  Seven (20.6%) 
reported receiving occupational therapy, and 16 (47.1%) reported receiving physical therapy 
(Table 5).  Seventeen (50.0%) respondents had hypertension prior to WNV, and seven (20.6%) 
had diabetes (Table 5).   
Many respondents reported having physical and cognitive symptoms at the time of the 
interview (Table 6).  When compared with symptoms that were present prior to their WNV 
illness, the largest changes before and after WNV illness were for memory loss (0 vs. 17), 
weakness (3 vs. 16), paralysis (0 vs. 9) and confusion (1 vs. 12). Four respondents experienced 
fatigue before WNV illness (11.3%), while 17 experienced fatigue at the time of the interview 
(p<0.001).  P-values could not be calculated for variables with any respondents with symptoms 
before WNV illness because there was nothing to compare the “after” variable to.  No 
respondents reported memory loss before WNV illness, yet 17 (50.0%) respondents reported 
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having memory problems at the time of the interview.  Weakness and myalgia followed with 16 
and 11 respondents reporting problems, respectively (Table 6).  Nine respondents reported still 
experiencing some form of paralysis after the WNV illness (26.5%).  Lightheadedness was 
reported the least with 3 (8.8%) patients reporting symptoms at the time of the interview (Table 
6).   
The duration of physical and cognitive symptoms ranged from zero to 1095 days; it may be 
longer, but duration of illness was calculated as the time between the date of illness onset and the 
date of interview (Table 7).  Weakness was the most frequently reported symptom and also had 
the longest duration (reported by all 34 respondents, lasting a median of 30 days).  Fatigue was 
the second most common symptom (reported by 30 respondents, lasting a median of 30 days) 
(Table 7).  More than half reported experiencing headaches, neck pain, myalgia, lower back 
pain, photophobia, difficulty concentrating, irritability, confusion and memory loss.  Tremors, 
insomnia, arthralgia, and lightheadedness were reported by less than 20 respondents.   
Twenty respondents missed work or school (58.8%) because of their illness (median duration of 
absence, 7 (range, 0 – 1023).  Thirty-one (91.2%) respondents reported reductions in their 
household activities (e.g. cooking, cleaning, chores) and outside-of-home activities and 32 
(94.1%) reported reductions in exercise due to WNV illness, 30 (88.2%) experienced difficulty 
walking because of their illness.  Twenty-seven respondents reported that it took more than 90 
days to “get back to normal” (79.4%) (Table 8). After the WNV illness 25 respondents reported 
needing no assistance for shopping (73.5%)  and 31 (91.2%) respondents reported needing no 
assistance for managing money (Table 9).   
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The mean of the all the maximum symptom duration for each non-neuroinvasive patient was 
222.40 days, while those with neuroinvasive disease had a mean of 272.21 days (Table 
10).Among respondents with non-neuroinvasive disease (n=5), the median age was 50 (range, 41 
to 68 years) (Table 11).  Four were under the age of 65 years and one was over 65 years of age.  
Two out of five patients were hospitalized, with a median length of stay of 3.5 days (range, 0 to 7 
days) (Table 11). Common acute symptoms included fatigue (100%), weakness (100%), 
myalgias (80%), headaches (60%), and neck pain (60%) (Table 12).  Underlying diseases 
included one respondent (20%) with heart disease (Table 11).  Symptoms reported at the time of 
the interview included weakness (20%), tremors (20%), arthralgia (20%), paralysis (20%) and 
memory loss (20%) (Table 12).   One respondent reported fatigue for at least 90 days (median: 
10, range, 7 to 998 days) and another respondent reported currently having memory loss (20%) 
(Table 13).Of the non-neuroinvasive respondents interviewed, 1 (20%) reported missing work 
for a median of 10 days (range, 0 to 180) (Table 13).  Two respondents reported being “not 
normal” for a median of 17 days (range 7 – 365) (Table 13). 
Respondents with neuroinvasive disease (n=29) had a median age of 57 (range, 36 to 89). 
Seventeen (58.6%) of the respondents were under the age of 65 and 12 (41.4%) were over the 
age of 65 (Table 11).  Twenty-eight (96.6%) were hospitalized, with a median length of stay of 
7.5 days (range, 0 to 82) (Table 11).  Underlying health conditions included heart disease 
(51.7%) and diabetes (24.1%) (Table 11).  Common symptoms during acute illness included 
fatigue (86.2%), weakness (100%), myalgias (79.3%), headaches (86.2%) and difficulty 
concentrating (58.6%).  Symptoms reported at the time of the interview included fatigue 
(58.6%), weakness (51.7%), myalgias (37.9%), confusion (41.4%), and memory loss (55.2%) 
(Table 12).  It took at least 90 days for 15 (51.7%) respondents to “get back to normal” 
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(mean:127.5, range, 0-1023).  For at least 90 days respondents reported weakness (37.9%, 
median: 30, range, 1 to 1095), and memory loss (34.5%, median: 9, range 0 to 1023).  Other 
activities respondents reported having difficulty with included: shopping (31.0%), heavy chores 
(27.6%), light housekeeping (27.6%), and transportation (27.6%) (Table 14). 
Of the neuroinvasive respondents interviewed, 12 (41.4%) reported their exercise being 
reduced after 90 days (Table 13).  Fifteen (51.7%) respondents reported taking at least 90 days 
to get back to normal, with a median length of 127.5 (range, 0 to 1023) (Table 13).  Eleven 
(37.9%) respondents reported experiencing weakness for at least 90 days, with a median length 
of 30 (range 1 to 1095) and ten (34.5%) respondents reported memory loss for at least 90 days, 
with a median of 9 days (range 0 to 1023).   
DISCUSSION 
 The long-term effects described in our study were similar to those reported from the New 
York 1999 outbreak, a study describing the long-term outcomes of WNV in 2002 in Tennessee, 
and in patients from St. Tammany Parish, Louisiana in 2002 12, 17, 35. Similar to our study, 
approximately 40% of patients in the New York 1999 outbreak did not return to their own homes 
immediately after discharge.  The common long-term signs and symptoms described in the New 
York 1999 study 18 months after initial illness included weakness (55.5%), fatigue (63.8 %), and 
memory loss (44.5%) 12. Shopping (40.0%) and heavy chores (55.9%) were also found to be 
affected after initial illness 12.  In Sejvar’s article, WNV patients also reported fatigue, myalgias, 
headache and memory eight months after initial illness 17. After one year, WNV patients from 
Tennessee reported fatigue (75%), weakness (58%), memory problems (25%) and headaches 
(25%) to be common long-term characteristics 35.  In a case report study, four cases of WNV 
 13
neuroinvasive disease reported improvements in strength within the 6-month period, but no 
patient attained full recovery 14.   
The Tennessee study also reported that 60% of persons with non-neuroinvasive illness 
were unable to return to pre-illness level activities due to lingering symptoms 35.  Although non-
neuroinvasive illnesses are considered less severe than neuroinvasive illnesses, our findings also 
suggest that non-neuroinvasive illnesses can be associated with long-term symptoms (Table 12 
& 13).  Of non-neuroinvasive Tennessee patients, 80% reported having missed work for a 
median of 4 days and one person reported a decrease in income directly related to the illness 38. 
Our results also suggest that long-term effects of WNV include paralysis (Table 6).  A study on 
recovery from paralysis found that after 18-months, previously paralyzed limbs in three patients 
had either poor or partial recovery 36.  The study also found that paralysis was acute and plateaus 
within hours of infection. Regardless of the severity of acute paralysis, it did not predict recovery 
and effects were variable among affected limbs 36.  In one case report, a 36-year-old woman had 
flu-like symptoms for one week and woke up to find herself paralyzed in the left leg 36 .  In 
comparison, a 44-year-old-man developed paralysis within 2-3 days, yet gained muscle strength 
in all limbs at nine months 36 . 
   The results of our study indicate that the consequences of WNV illness may be more 
serious and prolonged than generally thought.  The median time needed to recover “back to 
normal” was 180 days.  Also, 88.2% of the patients in our study required hospitalization, over 
half missed school or work after the WNV infection and 67.7% reported that their exercise, 
household, and outside-of-home activities were reduced for more than 3 months (Table 8).   
 Advanced age (>50) is the greatest risk factor for severe neuroinvasive disease, long-term 
morbidity, and death from WNV 4.  As others have suggested, our study found that preexisting 
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health conditions were common among respondents with neuroinvasive disease and may be 
independent risk factors for severe illness and death 3, 2, 25. Although non-neuroinvasive disease 
is considered a milder form than neuroinvasive disease, our findings suggest that non-
neuroinvasive disease can also be associated with long-term morbidity.  Twenty percent of 
respondents with non-neuroinvasive disease reported fatigue, tremors, arthralgia, paralysis and 
memory problems at the time of the interview.  Memory loss (20%) and fatigue (20%) was also 
experienced by non-neuroinvasive respondents for at least 90 days (Table 13).  Non-
neuroinvasive disease can result in work absenteeism, and extended recovery periods.  Further 
study of person with non-neuroinvasive WNV illness is important to better understand the 
spectrum of potential morbidity from this disease. 
Our findings have several limitations.  First, interviews were conducted several months to 
years after the infection, and recall bias could have influenced responses.  Those who were 
mentally affected with WNV illness may have over exaggerated or under attributed their 
symptoms to WNV illness.  Second, in persons with continuing symptoms, duration of illness 
was calculated as the time between the date of illness onset and the date of interview and could 
have resulted in an under-estimate of actual duration.  In addition, because persons with milder 
illnesses might have been less likely to seek medical care and therefore less likely to be tested, 
our study probably reflects the more severe characteristics of West Nile virus disease. Because 
WNV illness disproportionately affects older persons, the presence of underlying health 
conditions may have contributed significantly to the observed outcomes. Due to small sample 
size, our estimates may be inaccurate.  Despite these limitations, the findings are similar to those 
in other studies and can contribute to our understanding of the impact of this disease on high risk 
populations.   
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CONCLUSION 
WNV infection leads to persistent morbidity and prolonged recuperation periods.  Long-
term effects include weakness, fatigue, paralysis, and memory loss. Long-term symptoms were 
found to also affect activities such as shopping, heavy chores, and transportation.  Everyday 
activities such as walking, exercise and household activities were also affected.  Although non-
neuroinvasive disease is considered less severe than neuroinvasive disease, our findings suggest 
non- neuroinvasive diseases can also have more serious long-term outcomes.  All persons at risk, 
especially those over age 65 and those with underlying medical conditions, should take 
appropriate personal precautions to prevent WNV infection 31.  Such measures include the use of 
insect repellents, wearing long, loose-fitting, and light-colored clothing when outside, and 
elimination of breeding habits near residences.  Since there is no treatment for WNV infection, 
preventive measures should be taken to avoid mosquito exposure and eliminate mosquito 
breeding grounds.   
  Public health education about WNV infection and surveillance of WNV human cases, 
bird deaths, and mosquitoes is also critical for improving the control of the WNV.  The mortality 
rates and potential long-term effects associated with WNV infections emphasizes the importance 
of continuing to develop effective methods of targeting preventive education to high-risk 
populations while continuing to pursue longer-term solutions such as vaccines to prevent 
emerging infection.  Further research is needed to document the long-term effects of WNV, 
especially in areas with a high number of WNV human cases with more non-neuroinvasive 
patients. Overall, WNV is an emerging infectious disease in evolution, with a variety of clinical 
symptoms and long-term effects which makes it a public health concern.
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 Table 1. WNV human cases and deaths, U.S. and Virginia, 1999 through July 16, 2005  
  1999 2000 2001 2002 2003 2004 2005 
United States        
   Human Cases 149 21 66 4156 9862 2539 41 
   Deaths 18 2 9 284 264 100 1 
Virginia        
   Human Cases 0 0 0 29 26 5  
   Deaths 0 0 0 2 1 1  
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 Table 2. Survey characteristics and outcomes requested from WNV study respondents, 
Virginia, 2002-2004. 
Demographics History of Health Health Care Personal Assessment 
Age High blood pressure Type of specialist used General Health 
Race Diabetes If hospitalized    Before WNV 
Ethnicity Seizure   Duration of hospitalization    After WNV 
 Cancer   Where discharged    Overall 
 Heart Disease Occupational Therapy  
 Stroke/TIA Physical Therapy  
 HIV infection Medications prescribed  
 Tobacco use   
 Alcohol use   
    
* Cases were asked if they were ever diagnosed with the above diseases, when, and if any medications were prescribed.  
The personal assessment was scored 0-4 according to the following scale: 4 = Excellent, 3 = Very good, 2 = Good, 1 = 
Fair, 0 = Poor, 9 = Do not remember, 8 refused. 
 
 
Table 3: Health outcomes assessed during telephone interviews of study respondents who 
met case definition of WNV disease, Virginia, 2002-2004 
Physical Health Cognitive Health Functional Health Lifestyle Impact 
Fatigue Confusion Transportation Work 
Headache Irritability Telephone Household Activities 
Neck Pain Lightheadedness Meal Preparation Outside-of-home activities 
Myalgias Difficulty Concentrating Light Housekeeping Exercise reduced 
Tremors Altered Mental Status Heavy chores Difficulty walking 
Lower Back Pain  Laundry Time to get back to "normal" 
Weakness  Light chores  
Insomnia  Managing medications  
Photophobia  Managing money  
Arthralgia  Shopping  
        
* The Instrumental Activities of Daily Living (IADL) were scored 0-3 according to the following scale: With no assistance = 0, with 
some assistance = 1, cannot complete = 2, N/A = 3. 
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 Table 4. Demographic and clinical characteristics of respondents vs. non-respondents, WNV cases, 
Virginia, 2002-2004 
Characteristic 
Total         
N (%) 
Respondents       
N=34 (%) 
Non-respondents     
N=26 (%) 
Test 
Statistic p-value 
      
Age       
   Median (range)  54.0 (4, 94) 56.5   (36, 89) 56.0   (7, 94) t-test 0.837 
   Mean (SD) 57.1 (19.4) 59.24 (15.12) 58.23 (22.41)   
Sex           
   Female 21 (35) 12 (35.3)   9 (34.6) X2 0.956 
   Male 39 (65) 22 (64.7) 17 (65.4)     
Race       
   White  57 (95) 31 (31) 26 (100) X2 0.72 
   Black  3 (5)  3 (8.8)  0   
Ethnicity           
   Non-Hispanic 37 (61.7) 29 (85.3) 8  (30.8)   
   Hispanic   6 (10)  5 (5)  1  (3.8)   0.041 
   Unknown 17 (28.3) 0 17 (65.4)   
Clinical syndrome           
  West Nile fever 16 (26.7) 6 (17.6) 10 (38.5) X2 0.035 
  Unknown   2 (3.3)    2 (7.7)   
  West Nile neuroinvasive        
disease 42 (70.0) 28 (82.3) 14 (53.8)     
• Encephalitis 19 (45.2) 13 (46.42)   6 (42.9)   
• Meningitis 18 (42.9) 11 (39.3)   7 (50.0)     
• Meningoencephalitis   4 (9.5)   3 (10.7)   1 (7.14)   
• Myelitis   1 (2.4)   1 (3.6)   0      
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 Table 5. Conditions present prior to WNV and hospital 
discharge status of WNV study respondents, Virginia, 2002-
2004 
 
Respondents 
N=34  
Characteristic No. %  
       
Existing conditions prior to WNV    
   Hypertension 17 50.0  
   Diabetes 7 20.6  
   Heart Disease 4 11.8  
   Cancer 3 8.8  
   Seizure 3 8.8  
   Stroke 1 2.9  
Hospital Discharge status 30 88.2  
   Home 22 64.7  
   Required Physical Therapy 16 47.1  
   Required Occupational Therapy 7 20.6  
   Other 5 14.7  
   Rehabilitation 3 8.8  
   Skilled nursing facility 3 8.8  
   Unknown 1 2.9  
* Responses of "do not remember" were excluded.   
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 Table 6.  Self-reported illness outcomes of WNV study respondents, Virginia, 2002-2004 
Symptom 
Number of patients 
reporting 
symptoms before 
illness             
n (%)   
Number of 
patients currently 
with symptoms     
n (%) p-value†
        
Physical        
   Fatigue   4 (11.3)     17 (50.0)   <0.001 
   Weakness  3 (8.8)   16 (47.1)  <0.001 
   Myalgias   3 (8.8)     11 (32.4)   0.016 
   Headache  1 (2.9)     9 (26.5)  0.016 
   Neck pain   3 (8.8)       9 (26.5)   0.031 
   Lower back pain  5 (14.7)     9 (26.5)  − 
   Arthralgia   2 (5.9)       9 (26.5)   − 
   Paralysis  0     9 (26.5)  − 
   Insomnia   2 (5.9)       8 (23.5)   − 
   Photophobia  3 (8.8)     6 (17.6)  0.125 
   Tremors   1 (2.9)       6 (17.6)   0.125 
   Arthralgia  2 (5.9)     9 (26.5)  − 
   Paralysis   0       9 (26.5)   − 
Cognitive        − 
   Memory Loss   0     17 (50.0)     
   Confusion  1 (2.9)   12 (35.3)  − 
   Irritability   1 (2.9)       6 (17.6)   − 
   Difficulty concentrating  2 (5.9)     8 ( 23.5)  − 
   Lightheadedness   1 (2.9)       3 (8.8)   − 
               
* Symptoms were scored 0-3 according to the following scale: never = 0, sometimes= 1, often = 2, always = 3, do not 
remember = 9. Reported include often, sometimes and always. Responses of "do not remember" or no response were 
excluded.   
† To obtain p-values through the McNemar test, outcomes were recoded to dichotomous variables; never and sometimes = 
0 and sometimes and often = 1. 
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 Table 7.  Type and duration of self reported symptoms, WNV study respondents, Virginia, 2002-
2004 
      
 
Number of 
respondents 
with symptom 
while ill         
n (%)  
Duration of Symptom   
_______________________________ 
Median Days          
Duration  (range) 
      > 7 Days > 90 Days   
Symptom      
Physical      
   Weakness   34 (100) 13 (38.2) 11 (32.4) 30   (1, 1095) 
   Fatigue  30 (88.2) 12 (35.3)   9 (26.5) 30   (0, 1023) 
   Myalgias   27 (79.4)   9 (26.5)   9 (26.5) 10   (0, 1095) 
   Neck pain  23 (67.6)   6 (17.6)   8 (23.5)   9   (0, 1095) 
  Arthralgia   16 (47.1)   3 (8.8)   8 (23.5)   4  (0, 1023) 
   Lower back pain  22 (64.7)   8 (23.5)   8 (23.5)   9  (0, 1095) 
   Headache   28 (82.4) 10 (29.4)    7 (20.6)   9.5 (0, 23) 
   Insomnia  17 (50)   3 (8.8)   7 (20.6)   0    (0, 1022) 
  Photophobia   22 (64.7)   9 (26.5)   7 (20.6)   9    (0, 1023) 
   Tremors  15 (44.1)   6 (17.6)   5 (14.7)   0    (0, 1023) 
Cognitive           
   Difficulty concentrating  20 (58.8)   7 (20.6)   6 (17.6)   8    (0,1095) 
   Irritability   19 (55.9)   6 (17.6)   6 (17.6)   7    (0, 1023) 
   Lightheadedness  15 (44.1)   5 (14.7)   3 (8.8)   0.5 (0, 1022) 
   Confusion   20 (58.8)   7 (20.6)   6 (17.6)   7    (0, 1095) 
   Memory loss  21 (61.8)   8 (23.5)  11 (32.4) 25.5  (0, 1095) 
            
*  Responses of "do not remember" or no response were excluded.   
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 Table 8. Lifestyle impact, WNV study respondents, VA 2002-2004 
 
Total 
Patients,       
Number 
respondents 
while ill (%)  
n (%)                            
Patients Reporting Duration   
_____________________________ 
Median days         
Duration (range) 
      > 7 Days > 90 Days   
Lifestyle Impact      
   Missed work or school   20 (58.8)   4 (11.8)   9 (26.5)     7 (0, 1023) 
   Household activities limited  31 (91.2) 10 (29.4) 13 (38.2)   60 (0, 1023) 
   Outside-of-home activities reduced   31 (91.2) 10 (29.4) 13 (38.2)   60 (0, 1023) 
   Exercise reduced  32 (94.1) 10 (29.4) 13 (38.2)   60 (0, 1023) 
   Difficulty walking   30 (88.2) 10 (29.4) 13 (38.2)   60 (0, 1023) 
   Time to get "back to normal"  −   7 (20.6) 27 (79.4) 180 (0, 1023) 
            
 
 24
 Table 9. Functional health outcomes of WNV study respondents, Virginia 
from 2002, 2004. 
  
Before illness          
no assistance         
n (%) 
After illness          
no assistance        
n (%) p-value 
    
Functional Health    
   Shopping 34 (100) 25 (73.5) − 
   Heavy Chores 34 (100) 26 (76.5) − 
   Light housekeeping 34 (100) 26 (76.5) − 
   Transportation 34 (100) 26 (76.5) − 
   Laundry 34 (100) 27 (79.4) − 
   Meal preparation 34 (100) 28 (82.4) − 
   Taking Medication 34 (100) 30 (88.2) − 
   Telephoning 34 (100) 30 (88.2) − 
   Managing Money 33 (97.1) 31 (91.2) 0.063 
        
* Excluded some assistance and cannot complete 
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 Table 10. Mean of maximum symptom duration between non-neuroinvasive vs. 
neuroinvasive WNV study respondents, Virginia, 2002-2004 
  
Non-Neuroinvasive   
N=5  
Neuroinvasive      
N=29  p - value 
Patient's max symptom 
duration     
Mean (SD) 222.40 (435.03)  272.21 (371.95) 0.789 
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 Table 11. Characteristics of respondents of WNV neuroinvasive disease and non-neuroinvasive disease, 
Virginia, 2002-2004 
  Total Non-neuroinvasive    Neuroinvasive     
 N (%) N=5 (%)  N= 29(%)  
All Cases        (N=34) 34 (100) 5 (100)  29 (100)  
Age median  56.5 50  57  
   Range (36-89) (41-68)  (36-89)  
   <65 21 (61.8) 4 (80)  17 (58.6)  
   ≥65 13 (38.2) 1 (20)  12 (41.4)  
Male (%) 22 (64.7) 2 (40)  20 (69)  
Females (%) 12 (20.6) 3 (60)  9 (31)  
Hospitalized 30 (88.2) 2(40)  28 (96.6)  
   Median days  7 3.5  7.5  
   Range 0-82 0-7  0-82  
Underlying health conditions      
   Heart disease 16 (47.1) 1 (2.9)  15 (51.7)  
   Diabetes 7 (20.6) 0  7 (24.1)  
   Seizure 3 (8.8) 0  3 (10.3)  
   Cancer 3 (8.8) 0  3 (10.3)  
   Stroke 1 (2.9) 0  1 (3.4)  
Hospital Discharge Status      
   Rehab 3 (8.8) 0  3 (10.3)  
   Skilled nursing facility 3 (8.8) 0  3 (10.3)  
   Home 22 (64.7) 5 (14.7)  17 (50)  
   Other 5 (14.7) 0  5 (17.2)  
   Physical Therapy 16 (47.1) 1 (3)  15 (51.7)  
   Occupational Therapy 7 (20.6) 0  7 (24.1)  
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 Table 12. Self reported symptoms of WNV study respondents of non-neuroinvasive disease and 
neuroinvasive disease, Virginia, 2002-2004 
 
Non-
neuroinvasive     
N=5   
Neuroinvasive        
N=29  
Symptoms  Before While Currently  Before While Currently
        
Physical        
   Fatigue 0 5 (100) 0  4 (13.8) 25 (86.2) 17 (58.6) 
   Weakness 0 5 (100) 1 (20)  3 (10.3) 29 (100) 15 (51.7) 
   Neck Pain 0 3 (60) 0  3 (10.3) 20 (69)   9 (31.0) 
   Myalgias 0 4 (80) 0  3 (10.3) 23 (79.3) 11 (37.9) 
   Headache 0 3 (60) 0  1 (3.4) 25 (86.2)   9 (31) 
   Tremors 0 3 (60) 1 (20)  1 (3.4) 12 (41.4)   5 (17.2) 
   Lower back pain 1 (20) 3 (60) 0  4 (13.8) 19 (65.5)   9 (31) 
   Insomnia 0 2 (40) 0  2 (6.9) 15 (51.7)   8 (27.6) 
   Photophobia 0 2 (40) 2 (40)  3 (10.3) 18 (62.1)   6 (20.7) 
   Arthralgia 0 1 (20) 1 (20)  2 (6.9) 15 (51.7)   8 (27.6) 
   Paralysis 0 2 (40) 1 (20)  0   8 (27.6)   8 (27.6) 
Cognitive        
   Difficulty concentrating 0 3 (60) 0  2 (6.9) 17 (58.6)   8 (27.6) 
   Irritability 0 3 (60) 0  1 (3.4) 16 (55.2)   6 (20.7) 
   Lightheadedness 0 2 (40) 0  1 (3.4) 13 (44.8)   3 (10.3) 
   Confusion 0 1 (20) 0  1 (3.4) 19 (65.5) 12 (41.4) 
   Memory loss 0 2 (40) 1 (20)  0 19 (65.5) 16 (55.2) 
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Table 13. Duration of lifestyle impacts and self-reported symptoms of WNV study respondents c, Virginia, 2002-2004 
 > 7 days  > 90 days  
Median day                     
Duration (range) 
  
Non-
neuroinvasive 
N=5 
Neuroinvasive  
N=29   
Non-
neuroinvasive 
N=5 
Neuroinvasive  
N=29  
Non-
neuroinvasive 
N=5 
Neuroinvasive  
N=29 
         
Lifestyle Impact         
   Missed work or school 2 (40) 2 (6.9)   1 (20)   8 (27.6)  10 (0-180)   9 (0-1023) 
   Household activities limited 3 (60) 7 (24.1)  1 (20) 12 (41.4)  10 (0-180) 30 (0-1023) 
   Outside-of-home activities 
reduced 3 (60) 7 (24.1)   1 (20) 12 (41.4)  10 (0-180) 30 (0-1023) 
   Exercise reduced 3 (60) 7 (24.1)  1 (20) 12 (41.4)  10 (0-180) 30 (0-1023) 
   Difficulty walking 3 (60) 7 (24.1)   1 (20) 12 (41.4)  10 (0-180) 30 (0-1023) 
   Time to get "back to normal" 2 (40) 5 (17.2) 
 
 2 (40) 
 
15 (51.7) 
 
 17 ( 7-365) 
  
127.5 (0-1023) 
 Illness Outcomes   
Physical                
   Weakness 3 (60) 10 (34.5)  0 11 (37.9)  10 (7-30) 30 (1-1095) 
   Fatigue 2 (40) 10 (34.5)   1 (20)   8 (27.6)  10 (7-998) 30 (0-1023) 
   Myalgias 2 (40)   7 (24.1)  0   9 (31.0)   10 (0-1095) 
   Neck pain 2 (40)   4 (13.8)   0   8 (27.6)  9 (0-10)   9 (0-1095) 
  Arthralgia 1 (20)   2 (6.9)  0   8 (27.6)  0   9 (0-1023) 
   Lower back pain 2 (40)   6 (20.7)   0   8 (27.6)  7 (0-10)   9 (0-1095) 
   Headache 2 (40)   2 (8)  0   7 (24.1)  9 (0-10)   9.5 (0-1023) 
   Insomnia 0   3 (10.3)   0   7 (24.1)  0 (0-0)   0 
  Photophobia 2 (40)   7 (24.1)  0   7 (24.1)  0   9 (0-1023) 
   Tremors 2 (40)   4 (13.8)   0   5 (17.2)  9 (0-10)   0 
Cognitive         
   Difficulty concentrating 2 (40)   5 (17.2)   0   6 (20.7)  7 (0-10)   8 (0-1095) 
   Irritability 1 (20)   5 (17.2)  0   6 (20.7)  7 (0-10)   7 (0-1023) 
   Lightheadedness 1 (20)   4 (13.8)   0   3 (10.3)  0 .50 (0-1022) 
   Confusion 1 (20)   6 (20.7)  0   6 (20.7)  0   7 (0-1095) 
   Memory loss 1 (20)   7 (24.1)   1 (20) 10 (34.5)  0   9 (0-1023) 
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Table 14.  Self-reported illness outcomes of WNV study respondents of non-neuroinvasive disease and 
neuroinvasive disease, Virginia, 2002-2004 
 Before  After 
 
Non-
neuroinvasive 
N=5 
Neuroinvasive  
N=29  
Non-
neuroinvasive 
N=5 
Neuroinvasive  
N=29 
Functional Health      
   Shopping 0 0  0 9 (31) 
   Heavy Chores 0 0  0 8 (27.6) 
   Light housekeeping 0 0  0 8 (27.6) 
   Transportation 0 0  0 8 (27.6) 
   Laundry 0 0  0 7 (24.1) 
   Meal preparation 0 0  0 6 (20.7) 
   Taking Medication 0 0  0 0 
   Telephoning 0 0  0 4 (13.8) 
   Managing Money 0 1 (3.4)  0 3 (10.3) 
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